ALT Altimmune Inc

Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021

Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021

GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial results on Wednesday, November 10, 2021.

Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the third quarter 2021 financial results and provide a business update.

Conference Call Information:

Date:Wednesday, November 10
Time:8:30 am Eastern Time
Domestic Dial-in:(844) 615-6509
International Dial-in:(918) 922-3148
Conference ID:5783655
Webcast:

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit .

Follow @Altimmune, Inc. on

Follow @AltimmuneInc on

Investor and Media Contact:

Will Brown

Chief Financial Officer

Phone: 240-654-1450

 



EN
03/11/2021

Underlying

ALTAltimmune Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altimmune Inc

 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The L...

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025 24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondary endpoints, including reductions in liver fat, inflammation and biomarkers of fibrosis GAITHERSBURG, Md., Nov. 11, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based t...

November 11, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from ...

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025 AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement Pemvidutide demonstrated significant reductions in liver fibrosis and improvements in non-invasive tests vs. placebo at 24 weeks GAITHERSBURG, Md., Nov. 07, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-bas...

November 7, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Third Quarter 2025 Financial Results and Business ...

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates 48-week Data from Phase 2b IMPACT Trial of Pemvidutide in MASH Expected Before Year End End-of-Phase 2 Meeting with FDA for MASH Program Scheduled in Fourth Quarter Executive Leadership Strengthened with Appointments of Chief Medical Officer, Chief Commercial Officer, and Chief Legal Officer Cash, cash equivalents and short-term investments of $211 million as of September 30, 2025 Webcast to be held today, November 6, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT)...

November 6, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Participate in Two Upcoming Investor Conferences

Altimmune to Participate in Two Upcoming Investor Conferences GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for one-on-one meetings at the following investor conferences: Stifel 2025 Healthcare ConferenceWednesday, November 12, 2025Fireside Chat at 10:00 a.m. ET Jefferies Global Healthcare ConferenceThursday, November 20, 2025Fireside Chat ...

November 5, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 ...

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option On track to complete the 24-week treatment period and announce topline results in 2026 GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the completion of patient enroll...

November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch